Compare ABM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABM | IMNM |
|---|---|---|
| Founded | 1909 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1994 | 2020 |
| Metric | ABM | IMNM |
|---|---|---|
| Price | $44.40 | $23.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $47.80 | $32.80 |
| AVG Volume (30 Days) | 764.2K | ★ 1.7M |
| Earning Date | 06-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 102.34 | 51.40 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $8,745,900,000.00 | $6,941,000.00 |
| Revenue This Year | $5.97 | N/A |
| Revenue Next Year | $3.45 | $1,127.34 |
| P/E Ratio | $32.31 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $36.96 | $7.96 |
| 52 Week High | $50.12 | $27.65 |
| Indicator | ABM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 74.40 |
| Support Level | $44.50 | $23.67 |
| Resistance Level | $46.53 | $25.10 |
| Average True Range (ATR) | 1.18 | 1.06 |
| MACD | -0.12 | 0.68 |
| Stochastic Oscillator | 59.06 | 99.51 |
ABM Industries Inc is a provider of integrated facility solutions. It offers its solutions through five segments: Business and Industry, Manufacturing and Distribution, Education, Aviation and Technical solutions. The company derives the majority of its revenue from the business and industry segment, which encompasses janitorial, facilities engineering, and parking services for commercial real estate properties and sports and entertainment venues, hospitals, as well as vehicle maintenance and other services to rental car providers. The company mainly operates in the United States of America.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.